Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Niclosamide Solution and Camostat for COVID-19
NCT04644705Phase 1Completed
- Sponsor
- Charité Research Organisation
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of niclosamide in coronavirus disease 2019 (COVID-19), sponsored by Charité Research Organisation. Primary endpoints: Treatment emergent number of Adverse Events up to 14 days, Maximum plasma concentration of niclosamide at 24 hours and 1 more. Started Nov 2020; status: completed.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04644705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644705.